Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
COMPASS Pathways ( (CMPS) ) just unveiled an update.
Compass Pathways announced an underwritten offering of American Depositary Shares (ADSs) and pre-funded warrants, expected to raise approximately $150 million, with the potential to reach $353 million if warrants are exercised. The proceeds will support ongoing Phase 3 trials for treatment-resistant depression and a late-stage PTSD program. The offering enhances Compass’s financial position to advance its mental health treatment innovations.
More about COMPASS Pathways
Compass Pathways plc is a biotechnology company committed to advancing patient access to innovative mental health treatments. It focuses on developing psilocybin-based therapies, particularly its proprietary COMP360 formulation, which is used alongside psychological support. The company is headquartered in London with offices in New York and San Francisco.
YTD Price Performance: -0.24%
Average Trading Volume: 959,092
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $283.3M
See more data about CMPS stock on TipRanks’ Stock Analysis page.
